Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Heron Therapeutics (HRTX) over the last 12 years, with Q3 2025 value amounting to $12.9 million.

  • Heron Therapeutics' Other Operating Expenses rose 1795.48% to $12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.9 million, marking a year-over-year decrease of 97.4%. This contributed to the annual value of $47.1 million for FY2024, which is 3039.19% down from last year.
  • Heron Therapeutics' Other Operating Expenses amounted to $12.9 million in Q3 2025, which was up 1795.48% from $11.6 million recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' Other Operating Expenses ranged from a high of $39.1 million in Q2 2022 and a low of $11.0 million during Q3 2024
  • In the last 5 years, Heron Therapeutics' Other Operating Expenses had a median value of $17.8 million in 2022 and averaged $20.8 million.
  • In the last 5 years, Heron Therapeutics' Other Operating Expenses surged by 8570.99% in 2021 and then plummeted by 4982.78% in 2022.
  • Quarter analysis of 5 years shows Heron Therapeutics' Other Operating Expenses stood at $35.4 million in 2021, then plummeted by 49.83% to $17.8 million in 2022, then plummeted by 30.64% to $12.3 million in 2023, then decreased by 10.31% to $11.1 million in 2024, then grew by 17.05% to $12.9 million in 2025.
  • Its last three reported values are $12.9 million in Q3 2025, $11.6 million for Q2 2025, and $12.3 million during Q1 2025.